|
|
 |
|
 |
 |
Print
|
|
|
CMS Proposed 2010 HOPPS Payments Include Decreases for Certain Blood Products and Very Modest Increases for Stem Cell Processing
Under a proposed rule for 2010 Medicare payments for hospital outpatient services, the Centers for Medicare and Medicaid Services (CMS) has proposed very small increases and in some instances modest decreases in payments for the most frequently transfused blood products. However, the agency proposes significant decreases in the payments for some infrequently used blood products. Proposed payments for laboratory bone marrow/stem cell processing codes modestly increase, but still lag notably below the actual costs of these services. Comments on the proposed rule are due to CMS by August 31.
Payments for Blood Products
The following table compares the proposed 2010 payment rates for blood products with current Medicare payment rates:
Payments for Blood Components
|
HCPCS |
Description |
2009 Final APC |
2010 Proposed APC |
2009 Final Payment Rate |
2010 Proposed Payment Rate |
%
Change |
|
P9010 |
Whole blood for transfusion |
0950 |
0950 |
$230.40 |
$207.95 |
-9.74% |
|
P9011 |
Blood split unit |
0967 |
0967 |
$31.12 |
$91.05 |
192.58% |
|
P9012 |
Cryoprecipitate each unit |
0952 |
0952 |
$42.46 |
$44.84 |
5.61% |
|
P9016 |
RBC leukocytes reduced |
0954 |
0954 |
$188.92 |
$187.93 |
-0.52% |
|
P9017 |
Plasma 1 donor frz w/in 8 hr |
9508 |
9508 |
$76.73 |
$75.28 |
-1.89% |
|
P9019 |
Platelets, each unit |
0957 |
0957 |
$73.25 |
$66.20 |
-9.62% |
|
P9020 |
Platelet rich plasma unit |
0958 |
0958 |
$394.95 |
$148.82 |
-62.32% |
|
P9021 |
Red blood cells unit |
0959 |
0959 |
$136.82 |
$141.53 |
3.44% |
|
P9022 |
Washed red blood cells unit |
0960 |
0960 |
$261.64 |
$270.09 |
3.23% |
|
P9023 |
Frozen plasma, pooled, sd |
0949 |
0949 |
$58.83 |
$53.49 |
-9.08% |
|
P9031 |
Platelets leukocytes reduced |
1013 |
1013 |
$111.67 |
$114.45 |
2.49% |
|
P9032 |
Platelets, irradiated |
9500 |
9500 |
$164.42 |
$160.12 |
-2.62% |
|
P9033 |
Platelets leukoreduced irrad |
0968 |
0968 |
$128.19 |
$126.00 |
-1.71% |
|
P9034 |
Platelets, pheresis |
9507 |
9507 |
$468.66 |
$461.09 |
-1.62% |
|
P9035 |
Platelet pheres leukoreduced |
9501 |
9501 |
$514.82 |
$519.79 |
0.97% |
|
P9036 |
Platelet pheresis irradiated |
9502 |
9502 |
$469.53 |
$358.24 |
-23.70% |
|
P9037 |
Plate pheres leukoredu irrad |
1019 |
1019 |
$653.50 |
$673.01 |
2.99% |
|
P9038 |
RBC irradiated |
9505 |
9505 |
$250.69 |
$221.84 |
-11.51% |
|
P9039 |
RBC deglycerolized |
9504 |
9504 |
$341.43 |
$330.90 |
-3.08% |
|
P9040 |
RBC leukoreduced irradiated |
0969 |
0969 |
$251.33 |
$252.91 |
0.63% |
|
P9043 |
Plasma protein fract,5%,50ml |
0956 |
0956 |
$15.62 |
$57.92 |
270.81% |
|
P9044 |
Cryoprecipitatereduced plasma |
1009 |
1009 |
$85.16 |
$94.58 |
11.06% |
|
P9048 |
Plasmaprotein fract,5%,250ml |
0966 |
0966 |
$196.27 |
$110.16 |
-43.87% |
|
P9050 |
Granulocytes, pheresis unit |
9506 |
9506 |
$1,669.99 |
$48.64 |
-97.09% |
|
P9051 |
Blood, l/r, cmv-neg |
1010 |
1010 |
$144.13 |
$146.73 |
1.80% |
|
P9052 |
Platelets, hla-m, l/r, unit |
1011 |
1011 |
$711.89 |
$720.24 |
1.17% |
|
P9053 |
Plt, pher, l/r cmv-neg, irr |
1020 |
1020 |
$649.24 |
$685.09 |
5.52% |
|
P9054 |
Blood, l/r, froz/degly/wash |
1016 |
1016 |
$101.68 |
$97.80 |
-3.82% |
|
P9055 |
Plt, aph/pher, l/r, cmv-neg |
1017 |
1017 |
$480.41 |
$408.02 |
-15.07% |
|
P9056 |
Blood, l/r, irradiated |
1018 |
1018 |
$226.31 |
$194.91 |
-13.87% |
|
P9057 |
RBC, frz/deg/wsh, l/r, irrad |
1021 |
1021 |
$424.67 |
$417.10 |
-1.78% |
|
P9058 |
RBC, l/r, cmv-neg, irrad |
1022 |
1022 |
$301.43 |
$281.53 |
-6.60% |
|
P9059 |
Plasma, frz between 8-24hour |
0955 |
0955 |
$75.62 |
$80.87 |
6.94% |
|
P9060 |
Fr frz plasma donor retested |
9503 |
9503 |
$64.25 |
$61.57 |
-4.17% |
Payments for Bone Marrow and Stem Cell Processing Services
CMS has proposed very modest increases in payments for bone marrow/stem cell processing codes 38207-38215, which were first recognized by the agency in 2008. The proposed payment rate for Codes 38207-38209 (cryopreservation and thawing codes) is $226.60 (compared with $221.59 now), and the proposed payment for Codes 38210-38215 (cell depletion codes) is $409.25 (compared with $400.19). It should be noted that since these payments are based on 2008 claims data, any more recent adjustments that hospitals have made in their charging practices are not yet reflected in CMS’ payments. Hospitals are encouraged to take steps now to ensure that their charges accurately reflect the actual costs of providing these services since CMS will base future payments on such charge data.
The following table compares 2009 payment rates for transfusion and cellular therapy procedures with CMS’ proposed 2010 payments for these services:
Payments for Procedural Codes
|
CPT/ HCPCS |
Description |
2009 Final APC |
2010 Proposed APC |
2009 Final Payment Rate |
2010 Proposed Payment Rate |
%
Change |
|
36430 |
Blood transfusion service |
0110 |
0110 |
$221.59 |
$226.60 |
2.26% |
|
36440 |
Bl push transfuse, 2 yr or < |
0110 |
0110 |
$221.59 |
$226.60 |
2.26% |
|
36450 |
Bl exchange/transfuse, nb |
0110 |
0110 |
$221.59 |
$226.60 |
2.26% |
|
36455 |
Bl exchange/transfuse non-nb |
0110 |
0110 |
$221.59 |
$226.60 |
2.26% |
|
36511 |
Apheresis wbc |
0111 |
0111 |
$759.70 |
$818.57 |
7.75% |
|
36512 |
Apheresis rbc |
0111 |
0111 |
$759.70 |
$818.57 |
7.75% |
|
36513 |
Apheresis platelets |
0111 |
0111 |
$759.70 |
$818.57 |
7.75% |
|
36514 |
Apheresis plasma |
0111 |
0111 |
$759.70 |
$818.57 |
7.75% |
|
36515 |
Apheresis, adsorp/reinfuse |
0112 |
0112 |
$2,033.73 |
$2,119.73 |
4.23% |
|
36516 |
Apheresis, selective |
0112 |
0112 |
$2,033.73 |
$2,119.73 |
4.23% |
|
36522 |
Photopheresis |
0112 |
0112 |
$2,033.73 |
$2,119.73 |
4.23% |
|
38206 |
Harvest auto stem cells |
0111 |
0111 |
$759.70 |
$818.57 |
7.75% |
|
38207 |
Cryopreserve stem cells |
0110 |
0110 |
$221.59 |
$226.60 |
2.26% |
|
38208 |
Thaw preserved stem cells |
0110 |
0110 |
$221.59 |
$226.60 |
2.26% |
|
38209 |
Wash harvest stem cells |
0110 |
0110 |
$221.59 |
$226.60 |
2.26% |
|
38210 |
T-cell depletion of harvest |
0393 |
0393 |
$400.19 |
$409.25 |
2.26% |
|
38211 |
Tumor cell deplete of harvest |
0393 |
0393 |
$400.19 |
$409.25 |
2.26% |
|
38212 |
Rbc depletion of harvest |
0393 |
0393 |
$400.19 |
$409.25 |
2.26% |
|
38213 |
Platelet deplete of harvest |
0393 |
0393 |
$400.19 |
$409.25 |
2.26% |
|
38214 |
Volume deplete of harvest |
0393 |
0393 |
$400.19 |
$409.25 |
2.26% |
|
38215 |
Harvest stem cell concentrate |
0393 |
0393 |
$400.19 |
$409.25 |
2.26% |
|
38220 |
Bone marrow aspiration |
0003 |
0003 |
$208.26 |
$211.31 |
1.46% |
|
38221 |
Bone marrow biopsy |
0003 |
0003 |
$208.26 |
$211.31 |
1.46% |
|
38230 |
Bone marrow collection |
0112 |
0112 |
$2,033.73 |
$2,119.73 |
4.23% |
|
38241 |
Bone marrow/stem transplant |
0112 |
0112 |
$2,033.73 |
$2,119.73 |
4.23% |
|
88184 |
Flowcytometry/ tc, 1 marker |
0433 |
0433 |
$16.50 |
$16.64 |
0.85% |
|
88185 |
Flowcytometry/tc, add-on |
0433 |
0433 |
$16.50 |
$16.64 |
0.85% |
|
88187 |
Flowcytometry/read, 2-8 |
0342 |
0342 |
$10.06 |
$10.68 |
6.16% |
|
88188 |
Flowcytometry/read, 9-15 |
0343 |
0343 |
$34.55 |
$35.70 |
3.33% |
|
88189 |
Flowcytometry/read, 16 & > |
0343 |
0343 |
$32.75 |
$35.70 |
9.01% |
|
G0364 |
Bone marrow aspirate &biopsy |
0340 |
0340 |
$42.69 |
$45.06 |
5.55% |
CMS proposes not to pay for the costs of harvesting and transplanting allogeneic stem cells in the outpatient setting. According to CMS, “Allogeneic transplants performed on Medicare beneficiaries are provided on an inpatient basis, and all services related to acquiring the stem cells from a donor (whether performed inpatient or outpatient) are billed and are payable under Medicare Part A through the IPPS MS-DRG payment for the stem cell transplant.”
AABB will submit comments to CMS regarding the proposed rule. The proposed rule will be posted in the July 20, 2009 edition of the Federal Register.
|
|
|
|
Last modified on 7/16/2009 4:02:11 PM
|
|
|
 |
|
 |
 |
|
 |
 |
|
 | What's New! |  |
 |
| AABB Weekly Report - March 5, 2010 |
|
| Details |
|  |
 |
| National Hemovigilance Program Launches to Track Adverse Events Associated with Blood Transfusion |
|
| Details |
|  |
 |
| AABB Statement on XMRV Task Force |
|
| Details |
|  |
 |
| Updated Circular of Information for Cellular Therapy Products |
|
| Details |
|  |
 |
| Association Bulletin #10-01 - Association Bulletin Listings |
|
| Details |
|  |
 |
| Current U.S. Blood Supply is Adequate to Handle Demands Resulting from Earthquake in Haiti |
|
| Details |
|  |
 |
| Emerging Infectious Disease Agents |
|
| Details |
|  |
 |
| Study Highlights Implications Of Influenza Pandemics On Blood Supplies |
|
| Details |
|  |
 |
| Cellular Therapies Subsections |
|
| Details |
|  |
 |
| Association Bulletin #09-08 - ISBT 128 Conditional Accreditation Status |
|
| Details |
|  |
 |
| AABB Launches Facebook Fan Page |
|
| Details |
|  |
|
|
|
|
|
|
|
|
|
|
|
|